- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04728269
Exploratory Study on Lactibiane Topic AD on Skin Flora and Barrier Reinforcement in Mild to Moderate Atopic Dermatitis
January 28, 2021 updated by: PiLeJe
Exploratory Study to Assess the Impact of a Cosmetic Product (Lactibiane Topic AD) on Skin Flora and Skin Reinforcement Barrier in Mild to Moderate Atopic Dermatitis
This exploratory study aims to evaluate the impact of a cosmetic product (Lactibiane Topic AD) vs placebo on skin flora and skin reinforcement barrier in mild to moderate atopic dermatitis using biometrological, biological and clinical parameters.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Pierre-Bénite, France, 69495
- Unité de Recherche Clinique en Immunologie - Lyon Sud
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject diagnosed with mild to moderate AD defined as SCORAD≤40 (Eichenfield et al. JAAD 2014).
- Subject with at least two symmetric AD lesions with comparable severity: Located either on upper extremities (left and right arms except hands) or lower extremities (left and right legs except feet), With an erythema ≥ 1 (mild to severe intensity), With a lesional area score ≥ 4 on both lesions with an authorized delta of two points between the two lesions, With a sufficient extent to allow all the investigations.
- Subject with I, II, III or IV skin phototype (according to Fitzpatrick's scale).
- For woman of childbearing potential (defined as all women physiologically capable of becoming pregnant): Negative urine pregnancy test at inclusion visit. Use of a highly effective method of birth control* during the study. * A highly effective method of birth control is defined as one which results in a low failure rate (less than 1%) when used consistently and correctly, such as implants, combined oral contraceptives, intrauterine device, double barrier methods (e.g. condom with spermicide), sexual abstinence or vasectomized partner.
- Subject with health insurance coverage according to local regulation.
- Subject having given his written informed consent.
Exclusion Criteria:
- Subject having a known hypersensitivity, allergy or contraindication to any ingredients contained within the investigational product or placebo.
- Subject having exposed his skin to natural or artificial UV within 8 weeks prior to the inclusion visit or intending to expose his skin during the study.
- Subject having performed phototherapy within 8 weeks prior to the inclusion visit or intending to perform phototherapy during the study.
- Subject having performed another physical treatment (e.g radiotherapy…) on the investigational areas within 6 months prior to the inclusion visit or intending to perform it during the study.
- Subject treated with systemic non-steroidal anti-inflammatory drugs (≥3 days) within 1 week before the inclusion visit.
- Subject treated with biological immunosuppressive drugs within 12 weeks prior to the inclusion visit or intending to be treated with it during the study.
- Subject treated with non-biological immunosuppressive drugs within 4 weeks prior to the inclusion visit or intending to be treated with it during the study.
- Subject treated with systemic corticoids within 1 week prior to the inclusion visit or planed during the study.
- Subject treated with systemic antibiotics within 7 days prior to the inclusion visit or planed during the study.
- Subject having applied topical immunomodulators, non-steroidal anti-inflammatory, corticoids or antihistamines on investigational limbs within 1 weeks prior to the inclusion visit.
- Subject having applied topical antibiotics or disinfectants on investigational limbs within 2 weeks prior to the inclusion visit.
- Subject having applied any other topical and/or care product after the last grooming prior to the inclusion visit.
- Subject having applied water or care product (except hands cleaning) within 12 hours prior to the inclusion visit.
- Subject having started, modified or stopped any other treatment/product within 4 weeks prior to the inclusion visit or intending to do so during the study that according to the investigator's judgment, could interfere with study results.
- Subject having significant medical condition that according to the investigator's judgment, deems inappropriate for study participation (e.g present or past malignancy, present or past skin condition…).
- Subject having significant dermatological condition or sign (e.g disease, scare, abundant hairiness, tanning mark…) that according to the investigator's judgment, could limit the observations or/and interfere with the interpretations.
- Subject taking part or having participated in another clinical study within 2 weeks prior to the inclusion visit.
- Subject under legal guardianship or incapacitation.
- Subject linguistically or psychologically unable of signing informed consent form and unable to comply with the protocol requirements according to the investigator's judgment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lactibiane topic AD
Cosmetical product Lactibiane Topic AD
|
Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
|
Placebo Comparator: Placebo
Placebo made with the same base as the cosmetical product
|
Application of placebo twice a day (morning and evening) on the symmetrical lesional area
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in skin flora composition
Time Frame: from baseline (Day 0) at Day 21
|
16S rRNA sequencing, qPCR
|
from baseline (Day 0) at Day 21
|
Change in skin flora composition
Time Frame: from baseline (Day 0) at Day 14
|
16S rRNA sequencing, qPCR
|
from baseline (Day 0) at Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin barrier status
Time Frame: Day 0, Day 14, Day 21
|
TransEpidermal Water Loss (TEWL)
|
Day 0, Day 14, Day 21
|
Patient Oriented SCORing Atopic Dermatitis
Time Frame: Day 0, Day 14, Day 21
|
Patient Oriented SCORing Atopic Dermatitis (POSCORAD): 0 - 103 (Higher values represent a worse outcome)
|
Day 0, Day 14, Day 21
|
SCORing Atopic Dermatitis
Time Frame: Day 0, Day 14, Day 21
|
SCORing Atopic Dermatitis (SCORAD) : 0 - 103 (Higher values represent a worse outcome)
|
Day 0, Day 14, Day 21
|
Clinical severity of lesional areas
Time Frame: Day 0, Day 14, Day 21
|
Scoring of lesional area by subject and investigator : 0-18 (Higher values represent a worse outcome)
|
Day 0, Day 14, Day 21
|
Manifestation of adverse local reactions
Time Frame: From Day 0 to Day 21
|
Subjects will use a diary to document any potential adverse reactions observed after product application
|
From Day 0 to Day 21
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 19, 2020
Primary Completion (Actual)
December 9, 2020
Study Completion (Actual)
December 9, 2020
Study Registration Dates
First Submitted
January 14, 2021
First Submitted That Met QC Criteria
January 23, 2021
First Posted (Actual)
January 28, 2021
Study Record Updates
Last Update Posted (Actual)
February 2, 2021
Last Update Submitted That Met QC Criteria
January 28, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DEABIOM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
-
AnaptysBio, Inc.RecruitingAtopic Dermatitis EczemaUnited States, Canada, Georgia, New Zealand
Clinical Trials on Lactibiane Topic AD
-
PiLeJeCompletedDiarrhea Predominant Irritable Bowel SyndromeFrance
-
PiLeJeBioFortisTerminatedVaginal CandidiasisFrance
-
The University of Hong KongCompletedAdolescent Behavior | Behavior, Sex | Sex, UnsafeHong Kong
-
Larena SASCompletedIBS - Irritable Bowel SyndromeItaly
-
University of North Carolina, Chapel HillRTI International; North Carolina Translational and Clinical Sciences InstituteCompleted
-
EMSWithdrawn
-
EMSWithdrawn
-
Addpharma Inc.Recruiting
-
Addpharma Inc.CompletedHypertensionKorea, Republic of